ABBVIE INC (4AB.DE) Stock Fundamental Analysis
FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 74 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 4AB was profitable.
In the past year 4AB had a positive cash flow from operations.
In the past 5 years 4AB has always been profitable.
4AB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
4AB's Return On Assets of 3.05% is fine compared to the rest of the industry. 4AB outperforms 77.33% of its industry peers.
Looking at the Return On Equity, with a value of 292.61%, 4AB belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 13.43%, 4AB belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 12.94%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.05% | ||
| ROE | 292.61% | ||
| ROIC | 13.43% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.6%
1.3 Margins
4AB's Profit Margin of 7.24% is fine compared to the rest of the industry. 4AB outperforms 78.67% of its industry peers.
In the last couple of years the Profit Margin of 4AB has declined.
4AB's Operating Margin of 30.43% is amongst the best of the industry. 4AB outperforms 88.00% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
4AB has a better Gross Margin (70.69%) than 65.33% of its industry peers.
4AB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.43% | ||
| PM (TTM) | 7.24% | ||
| GM | 70.69% |
OM growth 3Y-5.46%
OM growth 5Y-6.07%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 4AB is still creating some value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
4AB has more shares outstanding than it did 5 years ago.
4AB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.13 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of 4AB (2.13) is better than 65.33% of its industry peers.
The Debt to FCF ratio of 4AB is 4.54, which is a neutral value as it means it would take 4AB, 4.54 years of fcf income to pay off all of its debts.
4AB has a better Debt to FCF ratio (4.54) than 81.33% of its industry peers.
4AB has a Debt/Equity ratio of 46.56. This is a high value indicating a heavy dependency on external financing.
4AB's Debt to Equity ratio of 46.56 is on the low side compared to the rest of the industry. 4AB is outperformed by 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 46.56 | ||
| Debt/FCF | 4.54 | ||
| Altman-Z | 2.13 |
ROIC/WACC1.68
WACC8.01%
2.3 Liquidity
A Current Ratio of 0.76 indicates that 4AB may have some problems paying its short term obligations.
4AB has a worse Current ratio (0.76) than 76.00% of its industry peers.
A Quick Ratio of 0.64 indicates that 4AB may have some problems paying its short term obligations.
The Quick ratio of 4AB (0.64) is worse than 77.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.64 |
3. Growth
3.1 Past
The earnings per share for 4AB have decreased by -6.30% in the last year.
4AB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
Looking at the last year, 4AB shows a small growth in Revenue. The Revenue has grown by 5.45% in the last year.
The Revenue has been growing by 11.11% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.3%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%6.49%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%8.39%
3.2 Future
The Earnings Per Share is expected to grow by 13.01% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.58% on average over the next years.
EPS Next Y23.45%
EPS Next 2Y18.9%
EPS Next 3Y16.07%
EPS Next 5Y13.01%
Revenue Next Year6.87%
Revenue Next 2Y7.53%
Revenue Next 3Y7.35%
Revenue Next 5Y6.58%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.12 indicates a rather expensive valuation of 4AB.
Based on the Price/Earnings ratio, 4AB is valued cheaper than 84.00% of the companies in the same industry.
4AB's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.35.
A Price/Forward Earnings ratio of 13.01 indicates a correct valuation of 4AB.
Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
4AB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.12 | ||
| Fwd PE | 13.01 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than 78.67% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 4AB indicates a somewhat cheap valuation: 4AB is cheaper than 78.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.36 | ||
| EV/EBITDA | 15.18 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.77
PEG (5Y)7.22
EPS Next 2Y18.9%
EPS Next 3Y16.07%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.54%, 4AB has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 10.34, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.00% of the companies listed in the same industry.
4AB's Dividend Yield is a higher than the S&P500 average which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.54% |
5.2 History
On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
269.03% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP269.03%
EPS Next 2Y18.9%
EPS Next 3Y16.07%
FRA:4AB (6/19/2025, 7:00:00 PM)
161.6
-0.6 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.24%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap285.45B
Analysts78.82
Price Target188.78 (16.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.54% |
Yearly Dividend5.42
Dividend Growth(5Y)7.72%
DP269.03%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.58%
Min EPS beat(2)0.02%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.84%
Min EPS beat(4)0.02%
Max EPS beat(4)1.28%
EPS beat(8)7
Avg EPS beat(8)0.85%
EPS beat(12)8
Avg EPS beat(12)0.35%
EPS beat(16)10
Avg EPS beat(16)0.22%
Revenue beat(2)1
Avg Revenue beat(2)0.51%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.35%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.35%
Revenue beat(12)4
Avg Revenue beat(12)-0.56%
Revenue beat(16)5
Avg Revenue beat(16)-0.82%
PT rev (1m)-1.69%
PT rev (3m)-5.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.33%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-0.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.61%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.12 | ||
| Fwd PE | 13.01 | ||
| P/S | 5.73 | ||
| P/FCF | 21.36 | ||
| P/OCF | 20.04 | ||
| P/B | 231.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.18 |
EPS(TTM)8.92
EY5.52%
EPS(NY)12.42
Fwd EY7.69%
FCF(TTM)7.56
FCFY4.68%
OCF(TTM)8.06
OCFY4.99%
SpS28.2
BVpS0.7
TBVpS-45.4
PEG (NY)0.77
PEG (5Y)7.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.05% | ||
| ROE | 292.61% | ||
| ROCE | 17.5% | ||
| ROIC | 13.43% | ||
| ROICexc | 14.15% | ||
| ROICexgc | 565.94% | ||
| OM | 30.43% | ||
| PM (TTM) | 7.24% | ||
| GM | 70.69% | ||
| FCFM | 26.82% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.6%
ROICexc(3y)15.06%
ROICexc(5y)13.83%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.16%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.46%
OM growth 3Y-5.46%
OM growth 5Y-6.07%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 46.56 | ||
| Debt/FCF | 4.54 | ||
| Debt/EBITDA | 2.56 | ||
| Cap/Depr | 12.17% | ||
| Cap/Sales | 1.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 63.55% | ||
| Profit Quality | 370.28% | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.64 | ||
| Altman-Z | 2.13 |
F-Score6
WACC8.01%
ROIC/WACC1.68
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.3%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%6.49%
EPS Next Y23.45%
EPS Next 2Y18.9%
EPS Next 3Y16.07%
EPS Next 5Y13.01%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%8.39%
Revenue Next Year6.87%
Revenue Next 2Y7.53%
Revenue Next 3Y7.35%
Revenue Next 5Y6.58%
EBIT growth 1Y9.32%
EBIT growth 3Y-5.38%
EBIT growth 5Y4.37%
EBIT Next Year22.05%
EBIT Next 3Y14.64%
EBIT Next 5Y10.77%
FCF growth 1Y-34.59%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-32.31%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%